|
|
|
| Webinar: Hype vs Hands On: The Truth About End-to-End Manufacturing Automation | Invetech dives into the real-world tools reshaping cell and gene therapy manufacturing. Forget the lab—today’s bottlenecks are infrastructure. Discover how end-to-end automation, modular platforms, and AI-driven analytics can slash timelines, cut variability, and hardwire compliance. Learn how to spot automation opportunities early and future-proof your process for fast-changing therapies and regulatory demands. Don’t scale the science—industrialize it. Click here to learn more. |
|
|
|
|
By Md Akram Hossain | Pharmaceutical firms are increasingly turning to enterprise resource planning (ERP) systems to modernize operations. These platforms unify core functions, including supply chain management, manufacturing, and financial planning and analysis. | |
|
|
|
| Finding The Right Aseptic Processing Approach | Article | AST | How should you approach building your aseptic processing line? Gain insight into the advantages of using a modular, configurable technology rather than custom fill-finish solutions. |
|
|
| Elevating AAV Manufacturing With Tailored Cell Lines | Webinar | Cytiva | Skillfully crafted cell lines can substantially enhance vector purity and yield. Watch to explore a portfolio of engineered cell lines and their potential to transform the landscape of AAV production. |
|
|
|
| Application Of A Sf-Rhabdovirus-Negative Platform For AAV Production | Application Note | By Thibaut Deschamps, Sandy McNorton, Kim Schrag, and Charlotte Javalet, MilliporeSigma | Discover a two-part system comprising a proven Sf-9 cell line devoid of Sf-rhabdovirus and a chemically defined medium engineered for it. Explore the performance of this medium for AAV2 production. |
|
|
|
|
| Manufacturing And cGMP For Cell And Gene Therapies | Article | Invetech | Successful CGT manufacturing requires therapeutic impact and ROI. Learn strategies to establish cGMP processes that advance development and support commercialization of cell and gene therapies. |
|
|
|
|
| Webinar: A Case Study for Viral Vector Process Impurity Profile: Evaluation of EndoCleave | Join us for a deep dive into the performance of Roche’s DNA endonuclease, EndoCleave, in AAV and LVV production. This webinar compares EndoCleave to other enzymes across key parameters—concentration, temperature, incubation time, and salt levels—using a HEK293 TTx platform, revealing insights to improve viral vector purity, safety, and scalability in gene therapy manufacturing. Click here to learn more. |
|
|
|
|
|
|
|
|
| Advancing the Future of Cell & Gene Therapy | This 11-12 November, Cell 2025 unites 1,000+ leading experts across the CGT value chain to solve key challenges, from scalable bioprocessing and regulatory hurdles to accelerating development timelines. Gain practical strategies across cell culture, therapy development, and CGT manufacturing, and hear from world-renowned leaders Bobby Gaspar (CEO, Orchard Therapeutics), Christof Von Kalle, (Director & BIH Chair, Research Clinic Luxemburg), and Dame Molly Stevens (University of Oxford). Register Now |
|
|
| Connect With Cell & Gene: |
|
|
|
